Abstract :Background/Aim: Serum Wisteria floribunda agglutinin positive Mac-2-Binding Protein (M2BPGi)
is a noninvasive glycolytion-marker for fibrosis. In this study, we analyzed serial changes of fibrous
markers during the clinical course of patients with chronic hepatitis C receiving daclatasvir/
asunaprevir therapy.
Methods: A total 31 chronic hepatitis C and cirrhotic patients recruited from September 2014 to
February 2017 were treated with daclatasvir/asunaprevir therapy for 24 weeks. Serum M2BPGi were
measured prior to, at the End of Treatment (EOT) and at 24 weeks after the completion of treatment.
We also measured Alpha-Fetoprotein (AFP) levels, serum albumin levels and the Fibrosis-4 (Fib 4)
index during the therapy and follow-up period.
Results: Thirty patients (96.7%) achieved Sustained Viral Response (SVR). AFP levels decreased
significantly. Serum albumin levels improved significantly during the clinical course. M2BPGi levels
and Fib-4 index continuously improved significantly.
Conclusion: Daclatasvir/asunaprevir therapy achieves high SVR rate and improve fibrosis markers
such as M2BPGi and Fib-4 index.